Ab Investor - Net Worth and Insider Trading
Ab Investor Net Worth
The estimated net worth of Ab Investor is at least $4.6 Billion dollars as of 2024-12-29. Ab Investor is the 10% Owner of Nasdaq Inc and owns about 58,182,426 shares of Nasdaq Inc (NDAQ) stock worth over $4.6 Billion. Ab Investor is also the 10% Owner of Achillion Pharmaceuticals Inc and owns about 1,483,810 shares of Achillion Pharmaceuticals Inc (ACHN) stock worth over $10 Million. Details can be seen in Ab Investor's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ab Investor has not made any transactions after 2012-05-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Ab Investor
Ab Investor Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ab Investor owns 7 companies in total, including Agile Therapeutics Inc (AGRX) , Nasdaq Inc (NDAQ) , and Mattersight Corp (MATR) among others .
Click here to see the complete history of Ab Investor’s form 4 insider trades.
Insider Ownership Summary of Ab Investor
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AGRX | Agile Therapeutics Inc | 2014-05-22 | 10 percent owner |
| NDAQ | Nasdaq Inc | 2012-05-23 | 10 percent owner |
| MATR | Mattersight Corp | 2011-12-19 | 10 percent owner |
 | | 2011-08-01 | other: Former 10% owner |
| | 2009-12-31 | 10 percent owner |
| | 2005-01-25 | 10 percent owner |
| | 2003-11-18 | 10 percent owner |
Ab Investor Latest Holdings Summary
Ab Investor currently owns a total of 2 stocks. Among these stocks, Ab Investor owns 58,182,426 shares of Nasdaq Inc (NDAQ) as of May 23, 2012, with a value of $4.6 Billion and a weighting of 99.78%. Ab Investor also owns 1,483,810 shares of Achillion Pharmaceuticals Inc (ACHN) as of December 31, 2009, with a value of $10 Million and a weighting of 0.22%.
Latest Holdings of Ab Investor
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NDAQ | Nasdaq Inc | 2012-05-23 | 58,182,426 | 78.42 | 4,562,665,847 |
| ACHN | Achillion Pharmaceuticals Inc | 2009-12-31 | 1,483,810 | 6.76 | 10,030,556 |
Holding Weightings of Ab Investor
Ab Investor Form 4 Trading Tracker
According to the SEC Form 4 filings, Ab Investor has made a total of 0 transactions in Nasdaq Inc (NDAQ) over the past 5 years. The most-recent trade in Nasdaq Inc is the acquisition of 300,000 shares on May 23, 2012, which cost Ab Investor around $2 Million.
According to the SEC Form 4 filings, Ab Investor has made a total of 0 transactions in Achillion Pharmaceuticals Inc (ACHN) over the past 5 years. The most-recent trade in Achillion Pharmaceuticals Inc is the sale of 95,200 shares on December 31, 2009, which brought Ab Investor around $305,592.
Insider Trading History of Ab Investor
- 1
Ab Investor Trading Performance
GuruFocus tracks the stock performance after each of Ab Investor's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ab Investor is 21.54%. GuruFocus also compares Ab Investor's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ab Investor within 3 months outperforms 7 times out of 11 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ab Investor's insider trading performs compared to the benchmark.
Performance of Ab Investor
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -2.47 | | | | | |
| Relative Return to S&P 500(%) | -2.84 | | | | | |
Ab Investor Ownership Network
Ab Investor Owned Company Details
What does Agile Therapeutics Inc do?
Who are the key executives at Agile Therapeutics Inc?
Ab Investor is the 10 percent owner of Agile Therapeutics Inc. Other key executives at Agile Therapeutics Inc include Chief Financial Officer Scott M Coiante , Chief Commercial Officer Amy Welsh , and director & Chief Executive Officer Alfred Altomari .
Agile Therapeutics Inc (AGRX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Agile Therapeutics Inc (AGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Agile Therapeutics Inc (AGRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Agile Therapeutics Inc (AGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Agile Therapeutics Inc Insider Transactions
Ab Investor Mailing Address
Above is the net worth, insider trading, and ownership report for Ab Investor. You might contact Ab Investor via mailing address: Arsenalsgatan 8c, Se-103 32, Stockholm V7 00000.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
